The ABC-12 Study 

ABC-12: Exploring the microbiome in patients with advanced biliary tract cancer (including cholangiocarcinoma and gallbladder cancer) in a first-line study of those receiving durvalumab in combination with gemcitabine and cisplatin.

This research study is evaluating the microbiome of patients undergoing treatment. 

All patients will receive the immunotherapy durvalumab plus chemotherapies gemcitabine and cisplatin.

Durvalumab plus gemcitabine and cisplatin was approved by NICE in January 2024 as the first line standard of care for those with inoperable cholangiocarcinoma or gallbladder cancer.  For more details, click here. 

For a patient guide to the first line treatment durvalumab plus gem/cis, click here

The study opened late in 2023 and is expected to close in at the end of March 2025.  Recruitment to the study is currently open in a number of locations including:

Birmingham
Cambridge
Cardiff
London
Manchester
Nottingham
Oxford
Wirral

If you are interested in taking part in the study, please speak to your oncologist.  

Chief Investigator: Dr Mairéad McNamara at The Christie, Manchester